OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

BIONTECH SE SPON. ADRS 1/  US09075V1026  /

Berlin
2024-04-23  8:04:04 AM Chg. +0.65 Volume Bid12:42:54 PM Ask12:42:54 PM Market Capitalization Dividend Y. P/E Ratio
82.30EUR +0.80% 0
Turnover: 0.00		 82.40Bid Size: 201 82.70Ask Size: 200 -EUR - 1.96
GlobeNewswire 04-22 BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
GlobeNewswire 04-07 Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...
TeleTrader 03-20 BioNTech Q4 revenue plunges 65% to €1.48B
GlobeNewswire 03-20 BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire 03-20 BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
GlobeNewswire 03-11 BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidat...
GlobeNewswire 03-07 BioNTech Announces Planned Retirement of Sean Marett
GlobeNewswire 03-06 BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update ...
GlobeNewswire 02-08 BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire 01-31 BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjuga...
GlobeNewswire 01-22 BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/...
TeleTrader 01-09 BioNTech sees $3.3B revenue for 2024, expanding into oncology
GlobeNewswire 01-09 BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 2023-12-21 BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Can...
GlobeNewswire 2023-12-18 BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
GlobeNewswire 2023-12-12 BioNTech to Inaugurate First African Site on December 18, 2023
TeleTrader 2023-11-06 BioNTech Q3 revenue plummets 74% to €895M
GlobeNewswire 2023-11-06 BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
GlobeNewswire 2023-10-26 Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Agains...
GlobeNewswire 2023-10-23 BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advance...
GlobeNewswire 2023-10-23 BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to ...
GlobeNewswire 2023-10-19 BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial wit...
GlobeNewswire 2023-10-16 BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023
GlobeNewswire 2023-10-16 Update Regarding Pfizer’s Statement on COMIRNATY-Related Write-Offs
GlobeNewswire 2023-09-28 Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vac...